Harry D. Bear

Collaborative Initiatives in the Care of Early Stage Breast Cancer: Reduction in Variation of Breast-Conserving Therapy.

Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunological activity.

Earlier chemotherapy for breast cancer: perhaps too late but still useful.

Taking action on the volume-quality relationship: how long can we hide our heads in the colostomy bag?

Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience.

Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.

Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.

The impact of physician and hospital volume on the quality of surgical outcomes.

Breast conservation therapy rates are no different in medically indigent versus insured patients with early stage breast cancer.

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.

Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Walter Lawrence, Jr.: a tribute to a surgical oncologist. "Been there, done that".

Sentinel node micrometastases and non-sentinel nodes in breast cancer: how much do we need to know?

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Tumor bed boost omission after negative re-excision in breast-conservation treatment.

Reaping the harvest from neoadjuvant therapy for breast cancer: reducing morbidity with sentinel lymph node biopsy.

Imaging multidrug resistance with 4-[18F]fluoropaclitaxel.

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.

Measuring circulating tumor cells as a surrogate end point for adjuvant therapy of breast cancer: what do they mean and what should we do about them?

Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis.

Completion axillary lymph node dissection for breast cancer: immediate versus delayed versus none.

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.

Effects of surgical excision on survival of patients with stage IV breast cancer.

IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function.

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.

Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells.

Neoadjuvant chemotherapy for operable breast cancer: individualizing locoregional and systemic therapy.

Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure.

A signature of immune function genes associated with recurrence-free survival in breast cancer patients.

Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.

Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells.

A gene transcription signature of obesity in breast cancer.

Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT.

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.